MDWerks Appoints Jeff Hopmayer to Board of Directors as Molecular Targeting Technology Platform Expands Across Industrial Markets
MDWerks appointed Jeff Hopmayer to its Board of Directors as the company transitions from technology development to commercial execution. The company reported its first commercial deployments began in Q2 2026, supported by an independently appraised IP portfolio valued at approximately $400 million.
Key figures
- Ip valuation
- $400 million
- Addressable market
- $1.8 trillion
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.